Who
Jacob Chacko
Director
Company insider
Files Form 4 as: Director, 4D Molecular Therapeutics; President and CEO, Oric Pharmaceuticals; Director, Turning Point Therapeutics; Chief Financial Officer, Ignyta.
In numbers
- Trades disclosed
- 107
- Buys
- 13
- Sells
- 36
- Bought
- $3.1M
- Sold
- $6.6M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 30 May 2014
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —675,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 16 Dec 2025filed 17 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $302K33,374 at $9.06 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —22,000 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —28,333 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —33,333 at $0.00 | filing |
| 15 Dec 2025filed 17 Dec 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —83,666 at $0.00 | filing |
| 6 Oct 2025filed 8 Oct 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $462K37,461 at $12.32 | filing |
| 1 Oct 2025filed 2 Oct 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $639K53,001 at $12.05 | filing |
| 30 Sep 2025filed 2 Oct 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $415K34,538 at $12.01 | filing |
| 22 Sep 2025filed 24 Sep 2025 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.4M125,000 at $10.80 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 16 Dec 2024filed 17 Dec 2024 | ORIC Oric PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $204K24,660 at $8.28 | filing |
| 15 Dec 2024filed 17 Dec 2024 | ORIC Oric Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —16,667 at $0.00 | filing |
News
ORIC Pharmaceuticals Plans Phase 3 Trial For Enozertinib After Promising Lung Cancer DataORIC · rttnews.com · 23 Oct 2026Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockORIC · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name Jacob Chacko; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.